Home › Funds › J. Stern & Co. LLP › ABT
J. Stern & Co. LLP position in ABT
ABBOTT LABORATORIES · Health Care
J. Stern & Co. LLP reported holding 247,689 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$24.5M, representing 2.53% of its reported portfolio and ranking #17 among its reported holdings. J. Stern & Co. LLP has disclosed ABT holdings in 11 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How J. Stern & Co. LLP's ABT position evolved
J. Stern & Co. LLP first disclosed a stake in ABT in Q4 2023 at 211,927 shares (US$24.0M). The position peaked in Q2 2025 at 351,707 shares, worth US$46.8M. Across 11 filings, J. Stern & Co. LLP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 247,689 shares valued at US$24.5M — a reduction of -63,540 shares quarter over quarter.. Notable position changes include a 12440% increase in Q4 2025 (shares fell 18% over the following quarter), a 99% trim in Q1 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 211.93K | $23.98M | New |
| Q2 2024 | 295.16K | $30.67M | New |
| Q3 2024 | 299.13K | $34.10M | Add |
| Q4 2024 | 315.43K | $35.68M | Add |
| Q1 2025 | 340.79K | $45.21M | Add |
| Q2 2025 | 351.71K | $46.78M | Add |
| Q3 2025 | 313.56K | $42.00M | Reduce |
| Q4 2025 | 39.32M | $39.32M | Add |
| Q1 2026 | 315.96K | $32.44M | Reduce |
| Q2 2026 | 311.23K | $28.24M | Reduce |
| Q3 2026 | 247.69K | $24.48M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.65B), Charles Schwab Investment Management (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 57.16M sh · $5.65B · Q3 2026
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 44.98M sh · $4.45B · Q3 2026
- Capital International Investors 35.46M sh · $3.51B · Q3 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Franklin Resources 20.44M sh · $2.36B · Q3 2026
- Deutsche Bank AG 17.69M sh · $1.75B · Q3 2026
- MFS Investment Management 14.93M sh · $1.48B · Q3 2026
More on J. Stern & Co. LLP
FAQ
How long has J. Stern & Co. LLP held ABT?
J. Stern & Co. LLP has disclosed ABT holdings in 11 of the last 12 reported quarters, going back to Q4 2023.
What is J. Stern & Co. LLP's current position in ABT?
As of Q3 2026, J. Stern & Co. LLP holds 247.69K shares of ABT (ABBOTT LABORATORIES), valued at $24.48M, representing 2.53% of its reported portfolio and ranking #17.
Has J. Stern & Co. LLP been buying or selling ABT?
In the latest 13F filing (Q3 2026), J. Stern & Co. LLP reduced its position in ABT. The position peaked in Q2 2025 at 351.71K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Charles Schwab Investment Management, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.